Pub Date : 2024-02-29eCollection Date: 2024-02-01DOI: 10.4244/AIJ-E-23-00006
Mirvat Alasnag, Mognee Alameer
{"title":"Interventional cardiology: a 2023 recap and what to expect in 2024.","authors":"Mirvat Alasnag, Mognee Alameer","doi":"10.4244/AIJ-E-23-00006","DOIUrl":"10.4244/AIJ-E-23-00006","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"10 1","pages":"10-11"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10900238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-29eCollection Date: 2024-02-01DOI: 10.4244/AIJ-D-23-00026
Michael Chiang, Ivan Wong, Shing Fung Chui, Chi Yuen Eric Wong, Pedro A Villablanca, Michael Kang-Yin Lee
{"title":"First-in-Asia native valve modified-BASILICA TAVR with CT fusion, complicated by annular rupture rescued with coil embolisation.","authors":"Michael Chiang, Ivan Wong, Shing Fung Chui, Chi Yuen Eric Wong, Pedro A Villablanca, Michael Kang-Yin Lee","doi":"10.4244/AIJ-D-23-00026","DOIUrl":"10.4244/AIJ-D-23-00026","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"10 1","pages":"60-61"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10900240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Continuous advances in the field of interventional cardiology have led to the development of drug-coated balloons (DCB). These represent a promising device for overcoming the well-known limitations of traditional metallic stents, which are associated with a persistent yearly increased risk of adverse events. This technology has the ability to homogeneously transfer the drug into the vessel wall in the absence of a permanent prosthesis implanted in the coronary vessel. Robust data support the use of DCB for the treatment of in-stent restenosis, but there is also currently growing evidence from long-term follow-up of large randomised clinical trials regarding the use of these devices in other scenarios, such as de novo small and large vessel disease, complex bifurcations, and diffuse coronary disease. Other critical clinical settings such as diabetes mellitus, high bleeding risk patients and acute coronary syndromes could be approached in the upcoming future by using DCB, alone or as part of a blended strategy in combination with drug-eluting stents. There have been important scientific and technical advances in the DCB field in recent years. The purpose of this paper is to review the most current data regarding the use of DCB, including the mid- and long-term follow-up reports on the safety and efficacy of this novel strategy in different clinical and angiographic scenarios.
{"title":"A 2024 scientific update on the clinical performance of drug-coated balloons.","authors":"Florin-Leontin Lazar, Horea-Laurentiu Onea, Dan-Mircea Olinic, Bernardo Cortese","doi":"10.4244/AIJ-D-23-00010","DOIUrl":"10.4244/AIJ-D-23-00010","url":null,"abstract":"<p><p>Continuous advances in the field of interventional cardiology have led to the development of drug-coated balloons (DCB). These represent a promising device for overcoming the well-known limitations of traditional metallic stents, which are associated with a persistent yearly increased risk of adverse events. This technology has the ability to homogeneously transfer the drug into the vessel wall in the absence of a permanent prosthesis implanted in the coronary vessel. Robust data support the use of DCB for the treatment of in-stent restenosis, but there is also currently growing evidence from long-term follow-up of large randomised clinical trials regarding the use of these devices in other scenarios, such as de novo small and large vessel disease, complex bifurcations, and diffuse coronary disease. Other critical clinical settings such as diabetes mellitus, high bleeding risk patients and acute coronary syndromes could be approached in the upcoming future by using DCB, alone or as part of a blended strategy in combination with drug-eluting stents. There have been important scientific and technical advances in the DCB field in recent years. The purpose of this paper is to review the most current data regarding the use of DCB, including the mid- and long-term follow-up reports on the safety and efficacy of this novel strategy in different clinical and angiographic scenarios.</p>","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"10 1","pages":"15-25"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10900242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-29eCollection Date: 2024-02-01DOI: 10.4244/AIJ-D-23-00034
Himanshu Gupta, Navjyot Kaur, Pruthvi C Revaiah
{"title":"Modified proximal optimisation technique for long left main interventions to prevent stent elongation.","authors":"Himanshu Gupta, Navjyot Kaur, Pruthvi C Revaiah","doi":"10.4244/AIJ-D-23-00034","DOIUrl":"10.4244/AIJ-D-23-00034","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"10 1","pages":"38-39"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10902656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21eCollection Date: 2023-09-01DOI: 10.4244/AIJ-D-22-00079
Hirofumi Hioki, Yusuke Watanabe, Akihisa Kataoka, Hideyuki Kawashima, Ken Kozuma
{"title":"Attention when performing transcatheter valve-in-valve procedures in degenerative INSPIRIS RESILIA valves: a case of malfunction in the expansion zone.","authors":"Hirofumi Hioki, Yusuke Watanabe, Akihisa Kataoka, Hideyuki Kawashima, Ken Kozuma","doi":"10.4244/AIJ-D-22-00079","DOIUrl":"https://doi.org/10.4244/AIJ-D-22-00079","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"9 2","pages":"168-169"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507603/pdf/AIJ-D-22-00079_Hioki.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41162820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21eCollection Date: 2023-09-01DOI: 10.4244/AIJ-D-22-00089
Adrienne Yh Chew, Chi-Hang Lee
Obstructive sleep apnoea (OSA) is a chronic sleep disorder characterised by recurrent cyclical episodes of upper airway collapse causing apnoea or hypopnoea. Despite being highly prevalent in patients with cardiovascular conditions, OSA has been a neglected component in cardiovascular practice. Fortunately, in the past few decades, increasing acknowledgement of the vulnerability of cardiac patients to OSA-related stressors and its adverse cardiovascular outcomes has made it a recognised cardiovascular risk factor in practice guidelines. Consequences of OSA include oxidative stress, endothelial dysfunction, autonomic dysfunction, and increased catecholamine release. The perturbations caused by OSA not only provide a clear mechanistic link to cardiovascular disease but also to poor outcomes after coronary revascularisation. This review article focuses on the correlation of OSA to coronary revascularisation outcomes. Our team reported that OSA is present in approximately 50% of patients undergoing coronary revascularisation. Importantly, untreated OSA was found to be an independent predictor of adverse events after both percutaneous coronary intervention and coronary artery bypass grafting. Although randomised trials did not confirm the benefits of OSA treatment in improving cardiovascular outcomes, these early trials were limited by poor treatment adherence. For now, systematic screening for OSA in patients undergoing coronary revascularisation is not indicated. Yet, with the proven benefit of OSA treatment in improving blood pressure control and quality of life, screening for and treatment of OSA is still indicated if patients have reported excessive daytime sleepiness and/or suboptimally controlled hypertension.
{"title":"Obstructive sleep apnoea and coronary revascularisation outcomes.","authors":"Adrienne Yh Chew, Chi-Hang Lee","doi":"10.4244/AIJ-D-22-00089","DOIUrl":"10.4244/AIJ-D-22-00089","url":null,"abstract":"<p><p>Obstructive sleep apnoea (OSA) is a chronic sleep disorder characterised by recurrent cyclical episodes of upper airway collapse causing apnoea or hypopnoea. Despite being highly prevalent in patients with cardiovascular conditions, OSA has been a neglected component in cardiovascular practice. Fortunately, in the past few decades, increasing acknowledgement of the vulnerability of cardiac patients to OSA-related stressors and its adverse cardiovascular outcomes has made it a recognised cardiovascular risk factor in practice guidelines. Consequences of OSA include oxidative stress, endothelial dysfunction, autonomic dysfunction, and increased catecholamine release. The perturbations caused by OSA not only provide a clear mechanistic link to cardiovascular disease but also to poor outcomes after coronary revascularisation. This review article focuses on the correlation of OSA to coronary revascularisation outcomes. Our team reported that OSA is present in approximately 50% of patients undergoing coronary revascularisation. Importantly, untreated OSA was found to be an independent predictor of adverse events after both percutaneous coronary intervention and coronary artery bypass grafting. Although randomised trials did not confirm the benefits of OSA treatment in improving cardiovascular outcomes, these early trials were limited by poor treatment adherence. For now, systematic screening for OSA in patients undergoing coronary revascularisation is not indicated. Yet, with the proven benefit of OSA treatment in improving blood pressure control and quality of life, screening for and treatment of OSA is still indicated if patients have reported excessive daytime sleepiness and/or suboptimally controlled hypertension.</p>","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"9 2","pages":"105-113"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507609/pdf/AIJ-D-22-00089_Chew.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21eCollection Date: 2023-09-01DOI: 10.4244/AIJ-E-23-00004
Ashok Seth
{"title":"Sharing knowledge and defining partnerships across boundaries through AICT-AsiaPCR.","authors":"Ashok Seth","doi":"10.4244/AIJ-E-23-00004","DOIUrl":"https://doi.org/10.4244/AIJ-E-23-00004","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"9 2","pages":"97-98"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507599/pdf/AIJ-E-23-00004_Seth.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41107336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号